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ABSTRACT
CBP501, a calmodulin-binding peptide, is an anti-cancer drug candidate and 
functions as an enhancer of platinum uptake into cancer cells. Here we show that 
CBP501 promotes immunogenic cell death (ICD) in combination with platinum 
agents. CBP501 enhanced a clinically relevant low dose of cisplatin (CDDP) in vitro 
as evidenced by upregulation of ICD markers, including cell surface calreticulin 
exposure and release of high-mobility group protein box-1. Synergistic induction of 
ICD by CDDP plus CBP501 as compared to CDDP alone was confirmed in the well-
established vaccination assay. Furthermore, cotreatment of CDDP plus CBP501 
significantly reduced the tumor growth and upregulated the percentage of tumor 
infiltrating CD8+ T cell in vivo. Importantly, the antitumor effect of CDDP plus CBP501 
was significantly reduced by anti-CD8 antibody treatment. Based on this novel effect 
of CBP501, we analyzed the combination treatment with immune checkpoint inhibitors 
in vivo. Mice treated with CBP501 in combination with CDDP and anti-PD-1 or anti-
PD-L1 showed an additive antitumor effect. These results support the conclusion that 
CBP501 enhances CDDP-induced ICD in vitro and in vivo. The findings also support 
the further clinical development of the CBP501 for enhancing the antitumor activity 
of immune checkpoint inhibitors in combination with CDDP.
INTRODUCTION
A calmodulin-binding peptide, CBP501, was 
previously described as a unique G2 checkpoint-directed 
agent [1] and as an enhancer of platinum uptake into 
cancer cells [2]. Therefore, CBP501 has been used in 
combination with platinum-based therapy in two Phase 
II clinical trials for patients with malignant pleural 
mesothelioma [3] and non-small cell lung carcinoma. 
Platinum agents are used to treat almost 50% of cancer 
patients [4] and, specifically, cisplatin (CDDP) is effective 
for the treatment of diverse solid tumors, including 
bladder, head and neck, lung, ovarian, and testicular 
cancers [5]. CDDP induces DNA crosslinking damage 
and thereby cancer cell death in the absence of DNA 
damage repair [6-7]. Cytotoxic drugs, including platinum 
agents, are thought to be immunosuppressive; however, 
recent studies show that some cytotoxic agents enhance 
antitumor effects by modulation of the immune system 
[8]. One of these effects is the induction of immunogenic 
cell death (ICD). 
ICD is a form of apoptotic cell death associated with 
release of endogenous danger molecules that activate three 
important hallmark events [9-13]: namely, (i) cell surface 
exposure of the endoplasmic reticulum (ER) chaperone 
molecule calreticulin (CRT) that functions as an “eat-me” 
signal and promotes uptake of antigens associated with the 
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dead cells by antigen-presenting cells (APCs) including 
dendritic cells [11-12]; (ii) release of ATP from dying cells 
that functions as a chemoattractant to recruit APCs and 
their activation; and (iii) release of high-mobility group 
protein box-1 (HMGB1) from dead cells that induces the 
maturation of APCs [13]. In particular, ER stress mediated 
phosphorylation of eIF2α (p-eIF2α) is required for cell 
surface exposure of CRT [14]; therefore, p-eIF2α is 
thought to be used as a biomarker for ICD induction [15]. 
These danger signals, in combination with cancer antigens, 
induce maturation of dendritic cells and can lead to an 
adaptive immune response against tumor cells, thereby 
mediating anticancer immunity [10]. Several studies 
show that cytotoxic drugs including methotrexate (MTX), 
doxorubicin and oxaliplatin (L-OHP) can induce ICD [11-
14, 16]. CDDP is thought to be a non-ICD inducer due to 
poor induction of ER stress response [17-18]; however, 
several reports show that low doses of CDDP induce ER 
stress response [19-22]. 
Here we show that a clinically relevant low dose of 
CDDP induces the upregulation of ICD markers that is 
enhanced by the coadministration of CBP501 in vitro. The 
results from the well-established vaccination assay shows 
that CBP501 plus CDDP, but not CDDP alone, induces 
ICD in vivo. Importantly, CDDP plus CBP501 induces 
significant antitumor effects that involve upregulation 
of the percentage of CD8+ T cells and downregulation of 
the percentage of M2-type macrophages in tumor tissues. 
The antitumor effect induced by CDDP plus CBP501 is 
significantly reduced by anti-CD8 antibody treatment. 
Furthermore, CBP501 plus CDDP, but not CDDP, 
significantly enhanced the antitumor effects anti-PD-1 and 
anti-PD-L1. 
RESULTS
CBP501 could enhance the antitumor activity of 
platinum agents including CDDP, carboplatin (CBDCA) 
and L-OHP and was most efficient in enhancing the 
activity of CDDP against CT26WT among three platinum 
compounds (Supplementary Figure 1). Therefore, we 
focused on the effect of CDDP plus CBP501. The Cmax 
concentrations for CDDP in blood or plasma of patients 
are 19-22 µM, [26-27]. We therefore used 20 µM CDDP 
for our in vitro experiments. Firstly, we measured several 
known ICD markers such as upregulation of p-eIF2α, 
cell surface expression of CRT and release of HMGB1 
to determine if clinically relevant low doses of CDDP 
or CDDP plus CBP501 induces ICD to CT26WT cells 
in vitro. Treatment with CBP501 alone did not affect 
the levels of these ICD markers (Figure 1A-1D). CDDP 
treatment alone induced dose-dependent upregulation 
of p-eIF2α (Figures 1A-1B) and cell surface CRT 
(Figure 1C) that was further enhanced by cotreatment 
with CBP501. Released HMGB1, an alarm or danger 
signal, was gradually increased in the culture medium 
of vehicle- or CBP501-treated cells in time dependent 
manner. CDDP treatment alone slightly increased HMGB1 
release; however, the combination treatment of CDDP 
plus CBP501 dramatically enhanced it (Figure 1D). 
Next, we performed the vaccination assay to evaluate 
the ICD induction in vivo. CT26WT cells treated in 
vitro with vehicle, MTX, CDDP or CDDP plus CBP501 
were inoculated in the flank of immuno-competent or 
-deficient BALB/c mice. Induction of cell death by 
treatment with compounds could not be detected at this 
time (Supplementary Figure 2A). A week later, the mice 
were re-challenged with untreated CT26WT cells at 1.6 
x 106 cells per mice in the opposite frank. We increased 
three times the number of live cells (cells for secondary 
inoculation) from 5 x 105 to 1.6 x 106, because by mice 
inoculated with vehicle treated cells rejected the secondary 
inoculated tumor cells when 5 x105 live cells were used 
(Supplementary Figure 2B). MTX was used as a potent 
inducer of ICD for the vaccination assay; however, 
MTX-treated cells did not enhance the tumor rejection 
compared to vehicle-treated cells (Figure 1E), suggesting 
that the sensitivity of this assay was not high enough to 
show the effect of MTX-induced ICD on CT26WT cells 
to the tumor rejection. Even though the sensitivity of the 
vaccination assay here was not high, inoculation of the 
cells treated with 10 µM CDDP plus CBP501 (P = 0.02) 
and 20 µM CDDP plus CBP501 (P = 0.0005) induced 
efficient rejection of the secondary challenge of CT26WT 
cells much more effectively than that observed by the 
inoculation of cells treated with CDDP alone (P = 0.08), 
which in addition induced better tumor rejection than that 
of the vehicle-treated cells in immunocompetent mice 
(Figure 1E). The rejection did not happen for any of the 
conditions in immunodeficient mice (Figure 1F). These 
results show that a clinically relevant low dose of CDDP 
plus CBP501 induced ICD better than CDDP alone in vitro 
and in vivo and promoted tumor rejection via host immune 
system.
Next, we evaluated the antitumor effect and the 
subsequent changes of tumor infiltrating lymphocytes after 
the treatment of CDDP plus/minus CBP501 in CT26WT 
implanted BALB/c mice. Intravenous administrations of 
CDDP alone or CDDP plus CBP501 were well tolerated, 
and the mean body weight losses were ~5% or ~10%, 
respectively (data not shown). CDDP treatment reduced 
the tumor growth that was significantly (P = 0.0008) 
enhanced by coadministration of CBP501 (Figure 2A). 
Analysis of tumor infiltrating cells by flow cytometry 
showed that treatment with CDDP plus CBP501 (P 
= 0.004), but not CDDP alone (P = 0.1), increased the 
percentage of CD8+ T cells (Figure 2B). When T cell 
subsets were depleted by function blocking anti-CD4 
antibody, the antitumor effect of CDDP plus CBP501 
treatment slightly enhanced; however, function blocking 
anti-CD8 antibody treatment significantly (P = 0.02) 
reduced the antitumor effect of CDDP plus CBP501 
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Figure 1: CBP501 enhances CDDP-induced immunogenic cell death both in vitro and in vivo. CT26WT cells were treated 
with 10-20 µM CDDP in combination with 0.5 µM CBP501 for 45 min, followed by a PBS wash and addition of fresh medium. A day 
later, collected cells were analyzed by immunoblotting using specific antibody against phospho-eIF2-alpha (n = 8) A.-B. Two days later, 
collected cells were analyzed by FACS with specific calreticulin antibody and propidium iodide C. The culture medium containing released 
HMGB1 was collected at 24, 48 and 72 h after treatment (n = 3). Quantification of the secreted HMGB1 was conducted by ELISA D.. 
Treated dying CT26WT cells and live untreated cells were subcutaneously inoculated to immuneocompetent E. or immunodeficient F. 
mice as described in materials and methods. Tumor engraftment/ progression of the right frank were monitored once per week. Data were 
compared by log-rank test. Error bar indicates SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with vehicle-treated cells, †P < 0.05, ††P 
< 0.001 compared with each platinum agent-treated cells 
Oncotarget78280www.impactjournals.com/oncotarget
(Figure 2C). These results show that a clinically relevant 
low dose of CDDP plus CBP501 induced ICD better than 
CDDP alone and the importance of CD8+ T cell activity 
in the antitumor effects induced by CDDP plus CBP501 
treatment.
Based on the above mentioned findings, we 
evaluated the efficacy of CDDP plus/minus CBP501 
when combined with immune checkpoint inhibitors, such 
as anti-PD-1 (Figure 3) and anti-PD-L1 (Figure 4) in 
CT26WT implanted BALB/c mice. Single treatments of 
CDDP (Figures 3D and 4D), anti-PD-1 (Figure 3F) and 
anti-PD-L1 (Figure 4F) but not CBP501 (Figures 3C and 
4C) showed minimal antitumor effects compared to the 
vehicle-treated mice (Figures 3B and 4B). Combination 
Figure 2: Upregulation of the percentage of CD8+ T cell in the tumor tissue by CDDP plus CBP501 treatment. CT26WT 
cells (5 x 105) were subcutaneously inoculated into BALB/c mice. Ten to eleven days later, the mice (n = 14) were treated intravenously 
with vehicle or 4 mg/kg of CDDP plus/minus 6 mg/kg of CBP501 (on days 1 and 8). The tumor growth curves A. and the percentage of 
CD8+ T cell in the tumor tissues on day 10 B. are showed. C. Eight days after tumor inoculation, CT26WT-tumor bearing mice (n = 4) 
were treated intraperitoneally with saline or 250 μg of anti-CD4 or anti-CD8 antibody (on days 1, 4, 7, 11 and 14) and intravenously with 4 
mg/kg of CDDP plus 6 mg/kg of CBP501 (on days 3 and 10). Error bar indicates SEM. *P < 0.05, **P < 0.01, ***P < 0.0001 compared with 
vehicle-treated mice. †P < 0.05, ††P < 0.001 compared with CDDP-treated mice. #P < 0.05 compared with CDDP plus CBP501-treated mice.
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Figure 3: Anti-tumor effects of CDDP or CDDP plus CBP501 in combination with anti-PD-1 antibody. Mice were 
subcutaneously inoculated into BALB/c mice. Seven days after inoculation, mice (n = 6) were treated intravenously with vehicle or 4 mg/
kg of CDDP plus/minus 6 mg/kg of CBP501 (on days 1 and 8) and intraperitoneally with saline or 200 μg of anti-PD1 antibody (on days 2, 
4, 9 and 11). Mean tumor volumes A. or each tumor volumes B.-I. were plotted versus the number of days after initiation of treatments. The 
groups were as follows: B. vehicle: black line, C. CBP501: blue line, D. CDDP: red line, E. CDDP + CBP501: green line, F. anti-PD-1: pink 
line, G. CBP501+anti-PD1 yellow line, H. CDDP+anti-PD1: brown line and I. CDDP+CBP501+anti-PD1: purple line. Error bar indicates 
SEM. *P < 0.05 compared with CDDP+CBP501-treated mice on day22. †P < 0.01 compared with CDDP+anti-PD1-treated mice on day22.
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Figure 4: Anti-tumor effects of CDDP or CDDP plus CBP501 in combination with anti-PD-L1 antibody. Mice bearing 
CT26WT tumor (n = 6) were prepared as descrived in Figure 3 and treated intravenously with vehicle or 4 mg/kg of CDDP plus/minus 6 
mg/kg of CBP501 (on days 1 and 8) and intraperitoneally with saline or 200 μg of and anti-PD-L1 antibody (on days 2, 4, 9 and 11). Mean 
tumor volumes A. or each tumor volumes B.-I. were plotted versus the number of days after initiation of the treatment. The groups were 
as follows: B. vehicle: black line, C. CBP501: blue line, D. CDDP: red line, E. CDDP+CBP501: green line, F. anti-PD-L1: pink line, G. 
CBP501+anti-PD-L1: yellow line, H. CDDP+anti-PD-L1: brown line and I. CDDP+CBP501+anti-PD-L1: purple line. Error bar indicates 
SEM. †P < 0.01 compared with CDDP+anti-PD-L1-treated mice on day21.
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treatments of CBP501 and CDDP (Figure 3E and 4E) 
effectively improved the antitumor effect of CDDP as 
seen in Figure 2A. Combination treatments of CBP501 
and immune checkpoint inhibitors (Figures 3G and 4G) 
did not improve the antitumor-effect of anti-PD-1 or anti-
PD-L1. The antitumor effect of anti-PD-1 but not anti-
PD-L1 was enhanced by combination treatment of CDDP 
and immune checkpoint inhibitor (Figures 3H and 4H); 
however, it did not reach statistically significant level (P 
= 0.068 and P = 0.61, respectively) compared to immune 
checkpoint inhibitor alone. Triple combination treatment 
of CDDP plus CBP501 and anti-PD-1 (Figure 3I) or 
anti-PD-L1 (Figure 4I) significantly (P = 0.0045 and P 
= 0.0078, respectively) enhanced the antitumor effect 
compared to double combination treatment of CDDP and 
immune checkpoint inhibitors, and the tumor eradication 
was confirmed in some mice (Figures 3I and 4I). Similar 
data were obtained in combination not only with CDDP 
but also with CBDCA (Supplementary Figure 3).
Next, we evaluated the tumor infiltrating T cells 
(Figure 5A) and tumor associated macrophages (TAMs) 
(Figure 5B) in the extracted tumor tissues by flow 
cytometry after the treatments of CDDP, CBP501 and 
anti-PD-1 each alone and in their combinations. Treatment 
Figure 5: Flow cytometric analysis of tumor infiltrating-lymphocytes after triple combination treatment of CDDP 
plus CBP501 and anti-PD1 antibody. CT26WT s.c. syngeneic mice (n = 4) were prepared as descrived in Figure 2A and treated as 
descrived in Figure 3. On day 11 after initiation of treatments, single-cell suspensions from tumor tissues were analyzed by flow cytometry 
using specific antibodies to monitor the percentage of T cells A. or TAMs B. in the tumor tissue. Error bar indicates SEM. *P < 0.05, **P < 
0.01 compared with vehicle-treated mice, #P < 0.05 compared with anti-PD1-treated mice.
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of CDDP alone and CDDP plus CBP501 tended to show 
increased CD8+ T cells as seen Figure 2B and reached 
statistically significant level (P = 0.01) with the triple 
combination (Figure 5A, bottom panel). The treatment 
of anti-PD-1 alone and triple combination of CDDP plus 
CBP501 with anti-PD-1 induced statistically significant 
increase (P = 0.048 and P = 0.023, respectively) in the 
ratio of M1-type TAM determined by F4/80+ MHCII+ 
(Figure 5B, top panel). The percentage of M2-type 
TAM determined by F4/80+ CD206+ was significantly 
downregulated by treatment of CDDP or CDDP plus 
CBP501 (P = 0.039 and P = 0.046, respectively), which 
exhibited a similar tendency even with the addition of 
anti-PD-1 treatment (Figure 5B, bottom panel). These 
results suggest that CDDP plus CBP501 induces ICD 
which led to the recruitment of CD8+ T cells into the tumor 
microenvironment. That effect enhanced the antitumor 
effects of anti-PD-1. The modulation of the ratio of TAMs 
also might have contributed to the antitumor activity of 
these combinations.
DISCUSSION
In this report, we showed that a clinically relevant 
low dose of CDDP could slightly upregulate ICD markers 
such as p-eIF2α (Figure 1A-1B), the cell surface CRT 
(Figure 1C) and the HMGB1 release (Figure 1D). These 
responses are dramatically augmented by the cotreatment 
with CBP501 in vitro. The results of the vaccination 
assays confirmed that CDDP or CDDP plus CBP501 
increase the immunogenicity of the treated cells (Figures 
1E-1F). Tesniere et al. [16] reported that CDDP could not 
induce ICD due to its poor property to induce ER stress 
response; however, the dose of CDDP employed by them 
was 150 µM, almost ten-fold higher than the clinically 
relevant levels, which might have induced necrosis [28]. 
Gonzalez et al. [29] mentioned that cisplatin at high doses 
could damage molecules involved in cellular energy 
supply (i.e., ATP) and also proteins directly or indirectly 
involved in the apoptotic process (i.e., p53, Bax, Bcl-2, 
and caspases), leading to necrotic cell death. In contrast, 
several reports showed that low doses of CDDP induce 
ER stress. Mandic et al. [19] showed that low doses (15-
20 µM) of CDDP induced upregulation of Grp78/Bip, 
another ER stress marker. Shi et al. [20] also showed that 
low doses of CDDP (10-40 µM) induced upregulation 
of Grp78/Bip and the inhibition of ER stress sensitized 
human lung cancer cells to CDDP. Di Blasio et al. [21] 
showed that low doses of CDDP (15 µM) treatment could 
induce the ICD responses including induction of p-eIF2α, 
cell surface CRT exposure and phagocytosis of CDDP-
induced dead cell. Aranda et al. [22] also showed that low 
dose of CDDP (2.5-5 µM) plus a vitamin B6 precursor 
pyridoxine, which sensitizes CDDP by interfering with 
redox metabolism [30] could induce ICD. From these 
studies and our results, it can be concluded that clinically 
relevant doses of CDDP induce ER stress response and 
lead to the induction of ICD.
We used MTX as a potent inducer of ICD for the 
vaccination assay; however, MTX-treated cells did not 
enhance the tumor rejection compared to vehicle-treated 
cells. Aaes et al. [31] showed that the mice injected MTX 
treated CT26 cells rejected tumor engraftment at a rate 
about 40%. This result is similar to our data. However, 
they used PBS that does not contain any cells as control 
in the vaccination assay. When we use PBS without cells 
as control, 80-90% of inoculated live cell could engraft in 
the tumor naïve balb/c mice in our experience (data not 
shown). From our results, we think that vehicle treated 
live cells should be used as control because vehicle treated 
cells also induced tumor rejection to a certain extent. Even 
though vehicle treated cells were somewhat immunogenic, 
CDDP plus CBP501 treatment significantly increased the 
immunogenicity and promoted the rate of tumor rejection.
As CBP501 increased ICD caused by CDDP, we 
analyzed the tumor infiltrating CD8+ T cells (Figures 2B 
and 5A, bottom panel) and TAMs (Figure 5B) of CT26WT-
tumor bearing mice after single or double combination 
treatment of CDDP and CBP501. Administration of 
CDDP plus CBP501 but not CDDP alone significantly 
increased CD8+ T cells in the tumor microenvironment 
(Figure 2B). This response correlated with the degree 
of antitumor effect (Figure 2A). Importantly, depletion 
of CD8+ T cell by a function blocking antibody led to 
the significant reduction of antitumor effects induced by 
CDDP plus CBP501 (Figure 2C). Administration of other 
ICD inducers, such as L-OHP plus cyclophosphamide 
[32] or doxorubicin [33] was reported to increase CD8+ 
T cell in the tumor tissues. These studies also support the 
conclusion that CDDP plus CBP501 induces ICD with 
increased percentages of CD8+ T cell in the tumor tissue.
Coadministration of immune checkpoint inhibitors, 
anti-PD-1 or anti-PD-L1, enhanced the antitumor effect 
of CDDP plus CBP501 and there was tumor eradication 
confirmed in about 17% of mice bearing CT26WT tumor 
(Figures 3-4). Flow cytometric analysis of the tumor 
infiltrating lymphocytes showed that the addition of CDDP 
plus CBP501, but not CDDP, significantly upregulated 
the percentage of tumor infiltrating CD8+ T cells induced 
by anti-PD-1 treatment (Figure 5A, bottom panel). The 
administrations of CDDP and CDDP plus CBP501 induced 
minimal upregulation of M1-type TAM (F4/80+MHC2+) 
(Figure 5B, top panel) and statistically significant 
downregulation of M2-type TAM (F4/80+CD206+) (Figure 
5B, bottom panel), which might have contributed to the 
antitumor effect of CDDP plus CBP501. Interestingly, 
the administration of anti-PD-1 induced statistically 
significant upregulation of M1-type TAM (F4/80+MHC2+) 
(Figure 5B, top panel). These intriguing findings prompted 
further investigation regarding the mechanistic effects of 
the combination treatments of CDDP plus CBP501 with 
anti-PD-1. Chen et al. [34] reported that deficiency of 
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PD-1 protein promotes M1 rather than M2 polarization 
of macrophages induced by zymosan and indicated that 
the PD-1 upregulation by zymosan delivered a negative 
signal into zymosan-stimulated bone marrow-derived 
macrophages, leading to the reduction of markers for M1 
macrophage. It is well known that the rapid growth of 
tumors is accompanied by a reduced microvessel density, 
resulting in chronic hypoxia that often leads to necrotic 
areas within the tumor [35]. Therefore, anti-PD-1 might 
upregulate M1-type TAM through the blockade of the 
negative feedback signal from newly expressed PD-1 
induced by HMGB1 in TAMs.
In summary, a clinically relevant low dose of CDDP 
slightly induced ICD which was dramatically increased 
by the addition of CBP501 in vitro and in vivo. The 
addition of CBP501 to CDDP increased CD8+ T cells and 
decreased M2-type TAMs in the tumor microenvironment 
in a syngeneic mice model. Noteworthy, the combination 
treatment of CBP501 and CDDP enhanced the antitumor 
activities of immune checkpoint inhibitors, anti-PD-1 
or anti-PD-L1. These results provide a rationale for the 
use of CDDP plus CBP501 in combination with immune 
checkpoint inhibitors in clinical trials.
MATERIALS AND METHODS
Cell lines and reagents
CT26WT cells (American Type Culture Collection, 
CRL-2638) were maintained in RPMI1640 medium 
supplemented with 10% fetal bovine serum (FBS) 
(Biowest) and 1% Penicillin-Streptomycin (Thermo Fisher 
Scientific K.K., cat.#15070-063). MTX (cat.# A6770) was 
obtained from Sigma-Aldrich Japan. CDDP was obtained 
from Nippon Kayaku Co., Ltd.. Diphenhydramine was 
obtained from Nisshin Pharmaceutical Co., Ltd.. Saline 
solition was obtained from Otsuka Pharmaceuticals. 
Trypsin/EDTA (cat.#25200-056) was obtained from 
Thermo Fisher Scientific K.K.. PBS (cat.#05913) was 
obtained from Nissui Pharmaceutical Co., Ltd.. Function 
blocking antibodies including anti-PD-1 (RMP1-14, 
cat.#BE0146), anti-PD-L1 (10F.9G2, cat.#BE0101), 
anti-CD4 (GK1.5, cat.#BE0003-1) and anti-CD8 (2.43, 
cat.# BE0061) were obtained from Bio X Cell. All other 
reagents used for this study were obtained from Sigma-
Aldrich Japan unless otherwise noted.
Compound treatment in vitro
Cancer cells at 0.8 - 1.6 x 105 were plated onto 
cell culture plates on the day before experiment. Next 
day, cells were treated with 10-20 µM CDDP plus/minus 
0.5 µM CBP501 for 45 min, followed by a PBS wash 
and the replacement of fresh medium. Twenty four- or 
forty eight-hours later, cells were collected and used for 
specific experiments including immunoblotting and flow 
cytometry.
Detection of phosphor-eIF2α
Experiments including preparation of whole cell 
lysates, immunoblotting, visualization of membrane bound 
proteins and measurement of the band intensity were 
performed as described previously [23]. Primary antibody 
for phospho-eIF2α (cat.#9721) was obtained from Cell 
Signaling Technology Japan k.k.. The band intensity of 
phospho-eIF2α was expressed as a ratio relative to that of 
the vehicle treated cells.
Detection of cell surface calreticulin
The cells treated with CDDP plus/minus CBP501 
were collected, and fixed with PBS containing 0.25% 
paraformaldehyde (Wako Pure Chemical Industries, 
Ltd., cat.#163-20145) for 5 min. After thrice washing 
with cold PBS containing 2% FBS, the cells were treated 
on ice with anti-calreticulin antibody (Abcam K.K., 
cat.#ab2907) for 30 min, followed by thrice washing 
with cold PBS containing 2% FBS and staining with 
alexa-488 conjugated donkey anti-Rabbit IgG (H+L) 
antibody (Thermo Fisher Scientific K.K., cat.#A-11055) 
for 30 min. The stained cells were washed thrice with cold 
PBS containing 2% FBS, treated with propidium iodide 
for 5 min and filtrated through a 35 µm nylon mesh prior 
to the flow cytometric analysis using BD FACSCalibur 
(BD Biosciences). Data analysis was performed by BD 
CellQuest software (BD Biosciences).
Detection of released HMGB1
The medium containing released HMGB1 
was collected into a microtube at 24, 48 and 72 h 
after treatment and kept at -80 degrees until ELISA 
analysis. Quantification of the released HMGB1 was 
conducted by HMGB1 ELISA kit II (Shino-Test Corp., 
cat.#3026054329) according to the manufacturer’s 
instructions. 
Syngeneic mice model
Female BALB/c or BALB/c-nude mice were 
obtained from Charles River Laboratories Japan, Inc. All 
animal studies were conducted according to protocols 
approved by institutional animal care committee of 
CanBas Co., Ltd. Six- to eight-week old female BALB/c 
mice were inoculated subcutaneously in a flank with a 
suspension of CT26WT cells (5 x 105 cells). Seven to 
eleven days later mice were apportioned into 6 to 8 groups 
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(4-6 mice/group) and treatments were initiated on day 1. 
Mice were intravenously treated with vehicle (saline) or 
CDDP (4 mg/kg) with or without CBP501 (6 mg/kg) on 
days 1 and 8 or days 3 and 10. Diphenhydramine (10 mg/
kg) was given intraperitoneally to mice at 15 min before 
chemotherapy. Vehicle (saline) or immune checkpoint 
inhibitors including anti-PD-1 or anti-PD-L1 were given 
intraperitoneally to mice (200 μg/mice) on days 2, 4, 9 and 
11. To deplete T cell subsets from mice, function blocking 
antibodies were treated as described previously [24-25] 
with slight modification. Anti-CD4 or anti-CD8 antibody 
were given intraperitoneally to mice (250 μg/mice) on 
days 1, 4, 7, 11 and 14. The size of tumor was measured 
twice or thrice weekly with a pair of calipers to calculate 
tumor volume by using the following formula: volume 
(mm3) = [(width)2 (mm) x length (mm)] / 2.
Well established vaccination assays were performed 
as described previously [11] with slight modification. 
Briefly, CT26WT cells were treated in vitro with vehicle, 
20 µM CDDP, double combinations of 10 - 20 µM CDDP 
plus 0.5 μM CBP501 45 min or 2 µM MTX for 4 h, 
followed by a PBS wash and harvesting the cells using 
trypsin/EDTA. The collected cells (3 x 106 cells in 200 μl 
of PBS) were subcutaneously inoculated in the left flank 
of six-week old female BALB/c or BALB/c-nude mice. 
A week later, live CT26WT cells (1.6 x 106 cells in 100 
μl of PBS) were subcutaneously inoculated again in the 
opposite (right) flank of the mice. Tumor engraftment/
progression of the secondary inoculated tumor was 
monitored once per week.
Analysis of tumor infiltrating lymphocytes
Tumor tissues from CT26WT bearing mice on day 
10 or 11 after first treatment were minced and treated with 
triple enzyme mix [type V hyaluronidase (Sigma-Aldrich 
Japan, cat.#H6254), type IV collagenase and DNAse I 
(Worthington Biochemical Corp., cat.#LS004188 and 
cat.#LS002139)] for 1 h to dissociate cell from the tissue. 
The cell suspension was filtered through a 70 µm nylon 
mesh and centrifuged to precipitate the cells, followed 
by ACK lysis buffer treatment (155 mM NH4Cl, 10 mM 
KHCO3 and 0.1 mM EDTA). The cell suspension was 
refiltered through a 40 µm nylon mesh and the single cell 
suspensions (1 x 106 cells) were pre-treated with anti-
CD16/32 antibody (biolegend, cat.#101302) and stained 
with specific antibody for multi-color flow cytometry 
analysis, including CD4 (Biolegend, cat.#100532), 
CD8 (BD Biosciences, cat.#553035), CD45 (Biolegend, 
cat.#103106), F4/80 (Biolegend, cat.#123110), MHC 
class II (MHC2) (Biolegend, cat.#107616) and CD206 
(Biolegend, cat.#141708) or DAPI (Thermo Fisher 
Scientific K.K., cat.#62248). Analysis was performed 
using CytoFLEX flow cytometer (Beckman Coulter K.K.), 
and obtained data were evaluated using FlowJo software 
(TOMY Digital Biology CO., LTD.)
Statistical Analysis
The statistical significance of the differences 
between groups was determined by unpaired two-tailed 
Welch’s t-tests. The results of vaccination assay were 
analyzed by the Kaplan-Meier method and compared 
using the log-rank test.
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